BioSpecifics Technologies - Ownership and Business Overview

Life ScienceCompany

BioSpecifics Technologies Ownership

Who owns BioSpecifics Technologies?

BioSpecifics Technologies is owned by Endo International. It was acquired on October 19, 2020.

BioSpecifics Technologies Business Overview

Where is BioSpecifics Technologies headquartered?

BioSpecifics Technologies is headquartered in Wilmington, Delaware.

What sector is BioSpecifics Technologies in?

BioSpecifics Technologies is a life science company.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.

BioSpecifics Technologies Corp.

Delaware Corporate Center II, 2 Righter Parkway, Suite 200,
Wilmington, Delaware 19803
United States,
(302) 842-8450
www.biospecifics.com

BioSpecifics Technologies Corp. is a commercial-stage biopharmaceutical company that discovers and develops a proprietary form of injectable collagenase (CCH), which is currently marketed by Endo, as XIAFLEX in North America for the treatment of Dupuytren's contracture and Peyronie's disease. Endo announced that it received FDA approval of CCH for the treatment of moderate to severe cellulite in the buttocks of adult women; Qwo is expected to be available commercially in the U.S. starting in the first half of 2021. The CCH research and development pipeline includes several additional potential indications including adhesive capsulitis and plantar fibromatosis.


 Subscribe to unlock this and 208,848
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.